课题基金 / 基金详情

The Role of Phosphatase CL100/MKP1 in Human Cancer

The Role of Phosphatase CL100/MKP1 in Human Cancer
磷酸酶 CL100/MKP1 在人类癌症中的作用
批准号:
7010738
负责人:
GEN SHENG WU
金额:
$24.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-02-05 至 2009-01-31

项目摘要

项目成果

GEN SHENG WU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): CL100/MKP1 is a member of the dual specificity protein phosphatase family that is able to dephosphorylate both the threonine and tyrosine residues on mitogen-activated protein (MAP) kinases, and thus plays a critical role in negatively regulating the activises of MAP kinases. CL100/MKP1 can also inhibit DNA damage-induced apoptosis. CL100/MKP1 is induced by a variety of stimuli including oxidative stress and growth factors. We have made the novel observation that CLt00tMKP1 is a transcriptional target of p53. The mechanism by which CL100/MKP1 is regulated, including the role of p53, and its relationship to human cancer remain to be determined. Our long-range goal is to understand the mechanisms of the signal transduction pathways in cancer cells and their role in chemosensitivity to chemotherapeutic drugs. The objective of this application is to study the role of the phosphatase CL100/MKP1 in p53-mediated cellular responses in human cancer. Exposure of cells to oxidative stress results in activation of p53, induction of CL100/MKP1, and activation of MJ_P kinases. These considerations suggest potential links among p53, CL100/MKP1, and MAP kinases. Understanding these links will provide insights into how the signal tranduction pathways interact. The novel aspect of our proposal is the potential cross talk between the p53 pathway and the MAPK pathway. The central hypothesis is that the dual phosphatase CL100/MKP1 is a mediator that links the p53 pathway to the MA,PK pathway. Our hypothesis is based on preliminary data produced in our laboratory showing that CL100tMKP1 is upregulated in a p53_ependent fashion. The rationale for the application is that, once the mechanism of p53-mediated regulation of CL100iMKP1 is known, modulation of this process may lead to the development of a novel strategy for cancer treatment. We will test our hypothesis and accomplish the objectives of this application by pursuing the following three specific aims: (1) Determine the regulation of CL100/MKP1 by p53; (2) Define the role of CL100fMKP1 in p53-mediated cell cycle regulation; and (3) Elucidate the role of CL100/MKP1 in p53-mediated apoptosis and chemosensitivity. Collectively, our studies will provide important and novel insights into the role of CL100/MKP1 in cell cycle and apoptosis control in human cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Atg5 in platinum-resistant ovarian cancer
  • 批准号:
    10307116
  • 项目类别:
  • 资助金额:
    $21.17万
  • 财政年份:
    2021
  • 负责人:
    GEN SHENG WU
  • 依托单位:
Developing targeted therapies for triple-negative breast cancer
  • 批准号:
    8760577
  • 项目类别:
  • 资助金额:
    $31.54万
  • 财政年份:
    2014
  • 负责人:
    GEN SHENG WU
  • 依托单位:
Developing targeted therapies for triple-negative breast cancer
  • 批准号:
    8884558
  • 项目类别:
  • 资助金额:
    $31.54万
  • 财政年份:
    2014
  • 负责人:
    GEN SHENG WU
  • 依托单位:
Developing targeted therapies for triple-negative breast cancer
  • 批准号:
    9115052
  • 项目类别:
  • 资助金额:
    $31.54万
  • 财政年份:
    2014
  • 负责人:
    GEN SHENG WU
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: